Rosnilimab

Phase 2Monoclonal antibody

AAnaptysBio, Inc.

Rosnilimab is one of 81 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actos

Takeda

Preclinical

2 2

Celexa

AbbVie

Preclinical

1 3

Voltaren

Cataflam

Plaquenil

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 7

Rosnilimab

AAnaptysBio, Inc.

Phase 2

1 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Disalcid

JJoslin Diabetes Center

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

Active, not recruiting·AAnaptysBio, Inc.·Phase 2·NCT06041269·420 enrolled

Alopecia Areata1 trial

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

Unknown status·AAnaptysBio, Inc.·Phase 2·NCT05205070·45 enrolled

Ulcerative Colitis1 trial

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

Active, not recruiting·AAnaptysBio, Inc.·Phase 2·NCT06127043·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rosnilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rosnilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rosnilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AnaptysBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AAnaptysBio, Inc.

Rosnilimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Alopecia Areata1 trial

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News